BRIVARACETAM 50mg. IP

An antiepileptic drug that treats focal (partial-onset) seizures in adults with epilepsy. (Ali A Asadi-Pooya, 2017) Provides broad-spectrum efficacy that is associated with a promising tolerability profile and a fast onset of action. (Henrik Klitgaard, 2016) A fast-acting antiepileptic drug with high lipid solubility and rapid brain penetration. (Pavel Klein, 2018) Reduces the seizure frequency in patients with drug-resistant focal epilepsy. (Simona Lattanzi, 2021) Shows statistically significant reductions in seizure frequency in patients with partial-onset seizures. (Farbod Khaleghi, 2017) A promising therapeutic choice in patients with epilepsy whose seizures persist despite adequate treatment. (Farbod Khaleghi, 2017) A highly effective in patients experiencing a secondarily generalized tonic-clonic seizure. (Pavel Klein, 2018) A viable alternative for patients with levetiracetam-associated adverse effects. (Katja Menzler, 2019) A safe, easy, and effective option in the treatment of patients with epilepsy, especially in the treatment of patients who have psychiatric comorbidities. (Felix Zahnert, 2018) A cost-effective and beneficial alternative to perampanel for the treatment of focal onset seizures. (Saku Väätäinen, 2020) A new therapeutic option that is effective in reducing seizures in brain tumor-related epilepsy patients. (Marta Maschio, 2020)